



Aurobindo Pharma receives tentative approval for Perindopril Erbumine Tablets and Escitalopram Oxalate Oral Solution

Aurobindo Pharma Limited is pleased to announce that the company has received tentative approvals from the US Food & Drug Administration (USFDA) for Perindopril Erbumine Tablets 2mg, 4mg, 8mg and Escitalopram Oxalate Oral solution 5mg (base) / 5ml

Perindopril Erbumine Tablets are the generic equivalent of Solvay Pharmaceuticals' Aceon® Tablets, falls under the CVS segment and indicated for the treatment of patients with essential hypertension.

Escitalopram Oxalate Oral solution are the generic equivalent of Forest Laboratories' Lexapro® Oral Solution, falls under the CNS segment and indicated for the treatment of major depressive disorder.

Aurobindo now has 85 approved ANDAs from the USFDA (61 Final approvals, 24 Tentative approvals)

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations

Aurobindo Pharma Limited

Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com